CD274 and renal cell adenocarcinoma: PDAC is known to be unresponsive to checkpoint inhibitors (ICIs) like atezolizumab or durvalumab, which bind to PD-L1, or pembrolizumab and nivolumab, which bind to PD-1, despite their high efficacy in other malignancies, such as non-small cell lung cancer (NSCLC), melanoma, or renal cell cancer (RCC) [165].